These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21194074)

  • 41. Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon.
    Boulestin A; Kamar N; Sandres-Sauné K; Legrand-Abravanel F; Alric L; Vinel JP; Rostaing L; Izopet J
    J Med Virol; 2006 Mar; 78(3):365-71. PubMed ID: 16419107
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The interferon sensitivity determining region: all hepatitis C virus isolates are not the same.
    Herion D; Hoofnagle JH
    Hepatology; 1997 Mar; 25(3):769-71. PubMed ID: 9049233
    [No Abstract]   [Full Text] [Related]  

  • 43. Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia.
    Giannini C; Petrarca A; Monti M; Arena U; Caini P; Solazzo V; Gragnani L; Milani S; Laffi G; Zignego AL
    Blood; 2008 Mar; 111(5):2943-5. PubMed ID: 18299456
    [No Abstract]   [Full Text] [Related]  

  • 44. Ukrainian health authorities adopt hepatitis C project.
    Devi S
    Lancet; 2020 Jul; 396(10246):228. PubMed ID: 32711786
    [No Abstract]   [Full Text] [Related]  

  • 45. [Progress and new challenges in hepatitis C].
    Moradpour D; Frossard JL
    Rev Med Suisse; 2013 Sep; 9(396):1563-4. PubMed ID: 24066462
    [No Abstract]   [Full Text] [Related]  

  • 46. Pharmaceuticals. Advocates protest the cost of a hepatitis C cure.
    Cohen J
    Science; 2013 Dec; 342(6164):1302-3. PubMed ID: 24337268
    [No Abstract]   [Full Text] [Related]  

  • 47. Miravirsen works against hepatitis C virus.
    BMJ; 2013 Apr; 346():f2069. PubMed ID: 23553883
    [No Abstract]   [Full Text] [Related]  

  • 48. [Development status of DAA against hepatitis C].
    Kato N; Nakagawa R; Goto K; Muroyama R; Matsubara Y
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():262-8. PubMed ID: 26845942
    [No Abstract]   [Full Text] [Related]  

  • 49. Repurposing of HDAC inhibitors toward anti-hepatitis C virus drug discovery: teaching an old dog new tricks.
    Zhao F; Liu N; Zhan P; Liu X
    Future Med Chem; 2015; 7(11):1367-71. PubMed ID: 26230876
    [No Abstract]   [Full Text] [Related]  

  • 50. [Research on viral hepatitic C treatment].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2011 Aug; 34(8):267. PubMed ID: 21853880
    [No Abstract]   [Full Text] [Related]  

  • 51. [The era of management of hepatitis c patients].
    Moradpour D; Hadengue A
    Rev Med Suisse; 2011 Sep; 7(307):1667-8. PubMed ID: 21987873
    [No Abstract]   [Full Text] [Related]  

  • 52. The drugs can work.
    Nat Rev Microbiol; 2012 May; 10(5):307. PubMed ID: 22629548
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The new era of hepatitis C treatment: still the tip of the iceberg?
    Gasbarrini A; Ponziani FR; Annichiarico BE; Siciliano M; Craxì A
    Eur Rev Med Pharmacol Sci; 2013 Sep; 17(17):2271-4. PubMed ID: 24065217
    [No Abstract]   [Full Text] [Related]  

  • 54. Silymarin for HCV infection.
    Polyak SJ; Oberlies NH; Pécheur EI; Dahari H; Ferenci P; Pawlotsky JM
    Antivir Ther; 2013; 18(2):141-7. PubMed ID: 23011959
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Silibinin: an old drug in the high tech era of liver transplantation.
    Ferenci P; Beinhardt S
    J Hepatol; 2013 Mar; 58(3):409-11. PubMed ID: 23195618
    [No Abstract]   [Full Text] [Related]  

  • 56. [Hepatitis C: in 2015, who should be screened first?].
    Nau JY
    Rev Med Suisse; 2015 Apr; 11(470):888-9. PubMed ID: 26050310
    [No Abstract]   [Full Text] [Related]  

  • 57. [Preclinical and clinical properties of vaniprevir (VANIHEP® Capsules 150 mg), a novel therapeutic agent for hepatitis C].
    Kinoshita K; Iwasa T; Takase A; Nakamura K
    Nihon Yakurigaku Zasshi; 2015 Sep; 146(3):159-70. PubMed ID: 26354016
    [No Abstract]   [Full Text] [Related]  

  • 58. Inhibition of hepatitis C entry: too soon to dismiss while many are still being denied treatment.
    Uprichard SL; Sainz B
    Gut; 2015 Apr; 64(4):690-1. PubMed ID: 25287483
    [No Abstract]   [Full Text] [Related]  

  • 59. [How to treat non-responders to antiviral bitherapy for hepatitis C?].
    Guyader D
    Gastroenterol Clin Biol; 2007 Mar; 31(3):317-24. PubMed ID: 17396096
    [No Abstract]   [Full Text] [Related]  

  • 60. [Boceprevir-benefit assessment by the Institute for Quality and Efficiency in Health Care (IQWiG) in accordance with § 35a SGB V (dosage evaluation)].
    Dignass A; Faiss S; Galle P; Layer P; Lerch M; Malfertheiner P; Wehrmann T; Zeuzem S;
    Z Gastroenterol; 2012 Jan; 50(1):20-1. PubMed ID: 22222793
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.